type 1 diabetes
Vertex builds in gene editing yet again, with $1.2bn Arbor deal
Phil Taylor
Arbor Biotechnologies, beta thalassaemia, CRISPR/Cas9, gene editing, sickle cell disease, type 1 diabetes, Vertex Pharma
0 Comment
FDA rejects Provention’s type 1 diabetes drug teplizumab
Phil Taylor
Diabetes, fda, metabolic disease, Provention Bio, teplizumab, type 1 diabetes
0 Comment
Artificial pancreas will be piloted in 1,000 diabetics, says NHS CEO
Phil Taylor
artificial pancreas, continuous glucose monitoring, insulin, NHS England, NICE, Simon Stevens, type 1 diabetes
0 Comment
Provention faces delay in FDA review of diabetes prevention antibody
Phil Taylor
antibody, fda, metabolic disease, Provention Bio, teplizumab, type 1 diabetes
0 Comment
FDA fast tracks type 1 diabetes cell therapy from Vertex
Phil Taylor
cell therapy, fda, FDA fast track, Regenerative medicine, type 1 diabetes, Vertex Pharma
0 Comment
FDA approves Tandem’s connected insulin controller
Phil Taylor
artificial pancreas, insulin, type 1 diabetes
0 Comment
Sanofi builds case for Toujeo in younger type 1 diabetics
Phil Taylor
Diabetes, insulin, Lantus, Sanofi, Toujeo, type 1 diabetes
0 Comment
News/ News/ R&D/ Top stories
Astellas cuts $795m deal with Pandion for type 1 diabetes drugs
Phil Taylor
Astellas, licensing, Pandion Therapeutics, type 1 diabetes
0 Comment